Stereotactic Radiosurgery (SRS) Registry

The Stereotactic Radiosurgery (SRS) patient registry aims to define national patterns of care in radiosurgery, with an eye to improving health care outcomes, supporting informed decision making, while potentially lowering the cost of care. The registry captures detailed treatment information for thousands of patients affected by brain metastases, benign brain tumors and arteriovenous malformations (AVMs).

Several diverse, high-volume academic and private medical centers across North America have participated in the registry since it was launched in 2015. Through generous financial and in-kind support from Brainlab, the registry features sophisticated, high fidelity data collection capabilities combined with automated analyses of tumor volume and dose-planning parameters designed to support clinical decision-making and improved healthcare outcomes for patients.

The SRS Registry Board of Directors oversees the governance, acquisition, analysis and dissemination of registry data. “The registry is helping to refine indications and techniques for radiosurgery, which should make radiosurgery safer and more effective for patients,” said Jason P. Sheehan, MD, PhD, FAANS, chair of the SRS Board of Directors. “As centers from around the country continue to join the registry, we will develop valuable information about practice patterns and quality indicators for radiosurgery. We will see how well our patients are doing over time, conduct practice improvements through comparative data and drive high-quality research through the creation of real-world evidence on the effectiveness of SRS treatments for particular diagnoses.”

Additional members of the SRS Board and Scientific Committee include Anthony L. Asher, MD, FAANS, of Carolina Neurosurgery and Spine Associates in North Carolina; Inga S. Grills, MD, of William Beaumont Medical Center in Michigan; James McInerney, MD, FAANS, of Penn State Milton S. Hershey Medical Center; Nader Pouratian, MD, PhD, FAANS, of UCLA; and Ronald E. Warnick, MD, FAANS, of Mayfield Clinic, Mercy Jewish Hospital in Ohio.

Dr. Warnick, whose hospital is a charter member of the SRS registry, observed that “the opportunities for the radiosurgery field are boundless when provided with a platform that allows providers to analyze institutional outcomes at this level. Centers can perform their own trend analyses, while refining treatments to the benefit of our patients. Registry participation requires the ongoing commitment of time and resources; however, the benefits have current as well as future value for patients, physicians and the field of neurosurgery in general. Our patients appreciate the degree of care demonstrated by collecting and optimizing their feedback, which is then included as part of their ongoing treatment plan. Physicians can contribute to research and analyses having lasting value, and all members of the care team can focus on improving patient outcomes. Because of this, it is a privilege to be a part of the SRS registry program.”

The NPA wishes to thank the following institutions for their contributions to the SRS registry:

  • Carolinas Medical Center
  • Duke Cancer Center
  • Mayfield Clinic, Mercy Jewish Hospital
  • Norton Cancer Institute
  • NYU Langone Medical Center
  • Penn State Milton S. Hershey Medical Center
  • Ronald Reagan UCLA Medical Center
  • The Valley Hospital
  • UF Health Cancer Center at Orlando Health
  • University of Rochester Medical Center
  • University of Southern California Keck Hospital
  • University of Texas Southwestern Medical Center of Dallas
  • University of Utah Huntsman Cancer Center
  • University of Virginia Health System
  • William Beaumont Hospital – Royal Oak
  • Yale New Haven Health System

Recent publications on SRS registry data include Quality of life outcomes for brain metastasis patients treated with stereotactic radiosurgery: pre-procedural predictive factors from a prospective national registry

The NPA focuses its clinical registries on promoting the quality of surgical care and providing surgeons with the means to assess risk-adjusted measures of the value and durability of treatment responses. Its registry programs and collaborative efforts assist in the understanding of patient perspectives on clinical outcomes and provide the ability to compare the relative effectiveness of various therapeutic interventions. Clinical data registries have become valuable tools to support evidence development, performance assessment, comparative effectiveness studies and adoption of new treatments into routine clinical practice. The NPA remains committed to its efforts to provide surgeons with the means to demonstrate value and validity in reporting and improving quality of surgical care through the collection and analysis of outcomes data.